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South Africa’s expenditure on tuberculosis (TB) research and development (R&D) is insignificant relative to both its
disease burden and the expenditure of some comparator countries with a minimal TB incidence. In 2010, the
country had the second highest TB incidence rate in the world (796 per 100,000 population), and the third highest
number of new TB cases (490,000 or 6% of the global total). Although it has a large TB treatment program (about
$588 million per year), TB R&D funding is small both in absolute terms and relative to its total R&D expenditure.
Given the risk and the high cost associated with drug discovery R&D, such neglect may make strategic sense.
However in this analysis it is shown that TB R&D presents a unique opportunity to the national treasuries of all
high-burden countries. Using two separate estimation methods (global justice and return on investment), it is
concluded that most countries, including South Africa, are under-investing in TB R&D. Specific investment targets
for a range of countries, particularly in areas of applied research, are developed. This work supports the outcome of
the World Health Organization’s Consultative Expert Working Group on Research and Development: Financing and
Coordination, which has called for “a process leading to the negotiation of a binding agreement on R&D relevant
to the health needs of developing countries”.Introduction
Tuberculosis (TB) is a bacterial disease that is caused by
pathogenic bacteria Mycobacterium tuberculosis (Mtb).
Although the number of new TB cases has been falling
since 2006, the disease is still a global epidemic. According
to the World Health Organization (WHO) [1], in 2011
there were 8.8 million incident cases of TB, 1.1 million
deaths from TB among HIV-negative people, 0.35 million
deaths from HIV-associated TB and almost 10 million chil-
dren orphaned as a result of parental deaths caused by TB.
South Africa is facing a massive TB epidemic [2], which
is threatening its social and economic well-being through
both the direct cost of treatment and the loss of productive
economic activity. Already the cost of treating TB (medi-
cines and hospitalization) is in excess of $588 million per
annum [3,4] (further details on the TB treatment budget
and the burden of disease are given in Additional file 1)Correspondence: david.walwyn@up.ac.za
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reproduction in any medium, provided the orand the estimated loss to the GDP is about $3.06 billion
per annum [5]. The HIV epidemic is amplifying the prob-
lem; not only is this epidemic directly increasing the num-
ber of TB patients, but it is also now recommended that
HIV patients receive isoniazid preventative therapy (IPT),
thereby adding a further approximately 1.5 million patients
to the 460,000 TB patients who require therapy or prophy-
laxis each year (according to the WHO [1], in 2010 only
124,049 HIV positive patients received IPT).
In response to this situation, the South African National
Department of Health has adopted the Negotiated Service
Delivery Agreement (NSDA) [6], which contains a number
of TB-specific objectives including a decrease in the burden
of disease from Mtb, an increase in the TB cure rate from
64% to 85%, and an increase in the TB treatment comple-
tion rate. However, the achievement of the NSDA goals will
require more than the wider utilization, and hence
additional expenditure, on diagnosis and treatment. Higher
completion rates in particular will only be possible with
new drugs.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TB requires 6 months of medication and for drug-resistant
TB at least 18 months, making patient adherence and
regimen completion extremely difficult. These extended
timelines are in sharp contrast to both the intrinsic killing
rates of these drugs in bacterial cultures and the action of
standard antibiotics, and it has been hypothesized that
upon drug exposure Mtb undergoes metabolic changes
rendering it immune to the bactericidal activity of TB
inhibitors [7]. New therapies that are short-acting, that are
effective against all forms of Mtb (latent, actively repli-
cating and drug-resistant forms) and that prevent the
emergence of Mtb granulomas, are urgently needed to
help combat the disease [7-10].
TB drug discovery requires public investment
Unfortunately, the development of new drugs and regi-
mens is expensive, time consuming and of uncertain out-
come. “How long” and “how expensive” remain disputed
quantities, and depend on a number of factors including
assumptions about success rates and patient cohort sizes.
However, the long time scales, large investments and low
rates of return make public investment essential.
Detailed support for this statement has been provided
in the Additional file 1. The risk-adjusted net present
value approach has been used in order to estimate total
development costs; the latter is a correction based on
the estimated success rate of the project at different
stages of development [11]. This calculation results in
the estimation of the parameter risk-adjusted net present
value (rNPV), which is used as the primary indicator of
project profitability.
Based on a range of values for the above parameters,
the rNPV for a novel TB drug development project has
been calculated (Figure 1).
It is clear from Figure 1 that the economics of TB drug
development, production and sale are insufficient to





















Figure 1 Project rNPV for development of first-line TB drug.Phase III (the product has a positive rNPV only at the
end of Phase III). This conclusion is the consequence of
the high rate of failure in drug discovery and the low TB
market size, and contradicts previously published data
[12,13]. Based on a detailed assessment of a wide cross-
section of data [14-17], it is the author’s opinion that the
TB Alliance report has overestimated the potential return
on investment due to several highly optimistic assump-
tions including success rate, market share, margin on sales
and net development costs.
Given the negative return prior to end of Phase III, it is
unlikely that the standard model in which drug candidates
are licensed to a private company (development partner) in
the preclinical stage will apply to TB drug discovery. To a
large extent, this conclusion is confirmed by the published
data on TB research. In 2010, 80% of the total TB R&D
expenditure came from public sector or philanthropic
funding [18,19] and many of the Phase II/III clinical trials
are being supported by public research institutions, devel-
opment agencies or product development partnerships, the
latter receiving much of their funding from philanthropic
organizations [19]. In the same year, there were only 4
private companies in the top 15 TB R&D funders, and of
the $127 million spent on basic TB research, only 5% came
from a private company [19]. It is clear that without
support for TB drug development from public funds, we
will not have new TB treatment drugs or regimens.
The analysis in this section applies specifically to the
case of TB drug development, and will not necessarily
apply to research on other types of products or services
such as diagnostics or operations research. However the
conclusions do present a compelling case for significant
public sector support for TB drug development, without
which such new drugs will not be developed or become
available. The returns for a private company are simply
inadequate to attract long term and significant investment
in the development of new TB drugs.
A different conclusion can be reached, on the other
hand, for the public sector, which forms the dominant
customer for TB treatment. New technologies and
products should result in significant savings to treatment
costs; despite this potential return, TB R&D has failed
historically to attract sufficient funding from either the
public or the private sector and places the illness in the
category of a neglected disease. Further details on R&D
funding for the latter now follow.
Neglected disease R&D
In the more general discussion of neglected disease R&D,
it is useful to distinguish between two disease categories,
namely Type II which is defined as “incident in both rich
and poor countries, but with a substantial proportion of
cases in poor countries” (TB is an example of a Type II































TB Incidence (No Cases/10,000 pop )
TB Incidence and Est TB R&D Expenditure (2010)
Figure 2 Estimated expenditure on TB R&D relative to TB disease
burden. Sources: WHO [1] and G-FINDER [24]. Note that the TB R&D
expenditure is a factored estimate based on the total reported
neglected disease R&D expenditure for each country; actual values
are unfortunately not available.
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as river blindness and sleeping sickness). For a long
period, neglected or poverty-related disease R&D was “at
a virtual standstill” [20]. Following various civil society ini-
tiatives, the situation over the past 10 years has improved,
with funding for R&D on Type II neglected diseases in-
creasing substantially. Examples of these initiatives include
the establishment of several open models for innovation
such as the Medicines Patent Pool, Open Source Drug
Discovery and World Intellectual Property Organization
Re:Search database; and the introduction of new incentive
mechanisms to address market failures such as the US
Food and Drug Administration priority review vou-
cher and the US Patent and Trademark Office‘s ’Pat-
ents for Humanity’ initiative.
The situation for Type III diseases remains largely
neglected with authors of the G-FINDER survey noting
that nearly 80% of the total neglected disease R&D funding
is spent on TB, HIV and malaria (all Type II), despite the
higher disease impact of several Type III diseases [21].
Moreover there are ongoing concerns about sustainability
of even Type II funding with calls for WHO member states
“to begin a process leading to the negotiation of a binding
agreement on R&D relevant to the health needs of deve-
loping countries” [22]. The concerns are focused on two
major limitations in the present situation, namely that
neglected disease R&D is heavily reliant on a few donors
(the Bill & Melinda Gates Foundation in particular), and
that the priorities for health R&D are determined by these
funders, rather than through a well-coordinated, global
R&D framework [20].
The report of the WHO’s Consultative Expert Working
Group on R&D (CEWG) recommends that “a binding in-
strument on R&D is necessary to secure appropriate
funding and coordination to promote R&D needed to ad-
dress the diseases that disproportionately affect developing
countries and which constitute a common global responsi-
bility” [22]. This report also proposes for all countries a tar-
get of 0.01% of the GDP for government-funded R&D
devoted to the health needs of developing countries, and
specifically for developing countries with ‘potential’ research
capacity, a commitment of 0.05 to 0.1% of GDP [22].
At the core of the debate about funding and priorities
is the role of governments within national states and
public health systems. To date, governments of countries
with high endemic levels of poverty-related diseases
(typically low-income countries) have contributed dis-
proportionally little towards neglected disease R&D, in-
cluding TB (Figure 2). Moreover, health research in
these countries also lacks an overall framework and a set
of well-defined national research priorities [23]. The
result is a double deficit, with both the total quantity of
health research being inadequate and the content of
what little research is being undertaken, being of limitedrelevance to national needs. It is also evident from
Figure 2 that donors in the United States and the United
Kingdom together account for more than 95% of TB
R&D, a surprising observation given the low TB inci-
dence of these two countries. The stark reality is that
most global TB research is being undertaken by two
high-income countries, whose objectives may not over-
lap with the priorities of low-income countries.
Few would argue with the statement that the right to
health is a human right, and that governments have an ob-
ligation to protect and develop the health of their own citi-
zens [25]. It can also be argued that in terms of global
justice principles, high-income countries have an obliga-
tion to the global poor [26,27], which may help to explain
the data in Figure 2. However, the efforts of high-income
countries to support TB R&D does not mean that middle-
or low-income countries are relieved from their obligations
towards their own citizens, and that adequate support for
health research should not be a priority in the allocation of
national funds within such countries. For instance coun-
tries such as India, China and South Africa, which have a
high TB incidence, also have a comparatively sizeable gross
expenditure on R&D (GERD) and could afford to spend
more on TB research (Figure 3). The present allocations of
less than 0.05% of GERD and lower to TB R&D seems
hardly appropriate given the urgency of the problem and
previously stated principles of global justice and health as a
human right.
Notwithstanding the moral and legal arguments, the
perceived correlation shown in Figure 3 is further counter-
intuitive considering the obvious benefits to a high-burden
country of developing improved TB treatment. From the
introduction, it is clear that a high TB burden equates to a
high social and economic cost, particularly to the national
treasury since most countries cover TB treatment within
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Figure 3 Estimated TB R&D expenditure relative to GERD and
TB burden. Sources: WHO [1], G-FINDER [24] and OECD [28].
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incidence countries, as a means of reducing costs in the
longer term, would be highly attractive. The reasons for this
ongoing neglect of health research remain obscure unless
one accepts the argument that national treasuries as a
general rule shun health research on the basis that such
investments carry high risk with limited hope of reward.
Indeed such a position is partly true; as noted earlier,
drug discovery in particular is expensive and high risk, and
such an undertaking can perhaps only happen in developed
countries with the appropriate supporting infrastructure
and required expertise. However risk and return is only a
part of the explanation; there is a great deal more to health
research than drug discovery. For instance, the CEWG
report recognizes the importance of other areas, including
research on novel vaccines, diagnostics, health systems,
operational and implementation issues, monitoring and
evaluation, and health-related policy issues [22]. Some of
these areas have the potential for high impact and low risk,
especially operational and implementation issues.
The CEWG report also reviews the history of targets
for national financing of health and health R&D, includ-
ing the Abuja target of 15% of GDP on health financing
[29] and the Commission on Health Research and De-
velopment (CHRD) target of 2% of national health ex-
penditure on health R&D [30], equivalent to 0.3% of
GDP. It is noted that most developing countries have
failed to meet either the Abuja or the CHRD targets,
and that more direct and proactive means are required
to stimulate global TB R&D. This failure has been ac-
knowledged by South Africa in the proceedings of the
2011 National Health Research Summit [31], which
noted that “there is inadequate funding of health re-
search by the Government of South Africa, especially by
the Department of Health”, with the department
investing about 0.37% ($49 million) of its 2011/2012
health budget ($13.2 billion) in health R&D, a shortfall
of $216 million vs. the 2% target adopted by the Health
Research Policy in South Africa in 2001.It is not clear how these targets were determined, or how
they relate to priorities and affordability. In the remainder
of this article, the determination of more justifiable and
realistic targets for health R&D, using the case study of TB
research in South Africa, is defined and discussed in more
detail. A Global Justice Index, based on GDP/capita, and a
Return on Investment (RoI) Factor are developed and
then combined to give a target for national TB R&D
expenditure for South Africa and other countries. Although
the specific example of TB is used as a case study, it is
noted that the same methodology could be applied equally
to the broader area of neglected diseases.
Computing the optimal TB R&D expenditure
Computing the optimal or justifiable TB R&D expenditure
for any country requires an assessment of the competing
priorities and the affordability of/return on investment
from such a public-financed program. In developing a
methodology for determining the appropriate expenditure
target, the following factors have been considered:
 The TB disease burden as measured by the
incidence rate per 10,000 population;
 The national R&D budget and the GDP per capita;
 The size of the national treatment program (which
can be considered as the capacity for budget savings).
These factors are used to compute the Global Justice
Index and the RoI Factor, which are now discussed in
more detail.
Global justice index
It is well known that national R&D intensity, calculated as
the ratio of GERD to gross GDP, correlates with GDP per
capita [32,33] (Figure 4). The interpretation of this correl-
ation has always been contested, with ongoing debate about
whether high GDP per capita is a consequence or a cause
of a high GERD/GDP ratio [34]. Undoubtedly the two vari-
ables are interlinked and will influence each other in a com-
plex, sometimes unpredictable manner. Nevertheless, GDP
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support research and development, and high levels of
income are typically associated with higher research
expenditure.
The allocation of research funds to specific areas and
research projects is almost entirely a discretionary process.
Given a pre-determined budget, allocation decisions are
made on the basis of strategic alignment, political factors
and a host of other considerations such as available
resources, expected impact and infrastructure. All nations,
and organizations within these countries, which have an
R&D budget, have as a consequence the opportunity to
invest in TB research.
This discretionary nature of research allocation decisions
lies at the core of resolutions such as the Abuja declaration
[29] and the CHRD target. It seems reasonable to propose
that nations which have discretion about how public funds
are allocated, should set aside a specific budget for health
research, and for the purposes of this analysis, to TB
research, based on the principles of global justice.
The question then becomes “what is a reasonable allo-
cation?” given the previously outlined obligations of
developed or wealthy nations to the global poor. The
CHRD target of 2% of national health expenditure for
health research is certainly a beginning point, but the
value is empirically stated and not theoretically derived.
Using data from the G-FINDER [24] and TAG [19]
reports, regression analysis has been used to derive a
correlation between GDP per capita and TB R&D. The
results of the regression follow:
For GDP/capita < 5,000; TB R&D = 0
For 5,000 < GDP/capita < 60,000; TB R&D =
4.2 × 10-10 × (GDP/capita)2 – 1.6-06 × (GDP/capita)
For GDP/capita > 60,000; TB R&D = 1.42
(where TB R&D is expressed as $/capita)
The source and calculated data are shown in Table 1






United States 47,040 278
Switzerland 45,236 2
United Kingdom 36,030 33
Australia 41,622 4
Japan 33,873 1
South Africa 10,676 3
China 6,746 0.40
India 1,143 6
Source: G-FINDER [24] and OECD [28].It is noted that the regression is based on the two
propositions of national responsibility in terms of global
justice and affordability based on national wealth. The
coefficients are significantly influenced by the two coun-
tries of United Kingdom and USA, both of which are
major funders of TB research. It is a non-linear function,
which has an upper and lower limit, with the lower limit
being $5,000 GDP per capita. In essence the correlation
enables the quantification of the extent of a country’s
obligation to support global TB research and has been
labeled as the Global Justice Index.
Return on investment (RoI) factor
An alternative and additional argument to the proposal
that high income countries should fund TB R&D based on
a global justice principles, is that high-burden countries
should act similarly since these countries have the most to
gain in terms of savings to TB programs and better
utilization of taxation revenues.
In many countries the public sector is the main financier
of TB treatment (in South Africa, 97% of incident cases are
treated in the public sector) [35]. In this capacity, national
treasuries will benefit from improved TB treatment in the
following respects:
 Reduction in treatment time and number of drugs:
with a new drug, it is likely that TB treatment time
can be reduced from 6 to 2 months, and the
number of drugs from 4 to 2. Most recent regimens
currently being tested contain fewer drugs and are
effective in shorter time periods [7-10]. In South
Africa, it is calculated that the net cost savings to
the National Treasury will be about $82 million per
annum; the latter figure is based on a reduction in
hospitalization costs for MDR-TB and lower drug
costs (presently $207 million and $14 million
respectively).
 Improved treatment outcomes: the present re-
treatment rate is about 15% of the total patientsDP and incidence
D Proposed target TB R&D (USD million)

























Recommended TB R&D Expenditure by country
Global Justic Index RoI Factor
Figure 6 Recommended TB R&D expenditure based on global
justice index and RoI factor.
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assumed that the re-treatment rate will fall to less
than 1% with an improved regimen, thereby saving a
further $89 million per annum (this assumption is
considered reasonable given the cure rates for
analogous bacterial infections).
 Job creation: the local manufacture, marketing and
distribution of a new drug will create jobs in the
chemical industry, the pharmaceutical industry and
the healthcare industry. It is not possible to specify
how many jobs and in which sector due to the
uncertainty of the commercialization route.
 Economic growth: the anticipated product revenue
of a new TB drug in South Africa alone will be
about $5 million per annum, which will replace
about $14 million of imported pharmaceuticals and
will reduce the total per patient treatment cost from
about $33 to $14 per patient course. Similar figures
could be expected for other countries.
These savings and benefits have already been mentioned
from a qualitative perspective. However, quantification of
these benefits is more difficult to define. In this analysis,
the following assumptions have been made:
 Program budget: before any cost savings can be
estimated, it is important to value the cost of the
existing program. This is calculated from the WHO
data on incidence and treatment cost per TB patient
(Figure 5).
 Extent of annual savings: the value of a R&D project
from the perspective of a national treasury can be
considered as the net present value of the savings over
the expected duration of the innovation. Estimating
the annual savings over a range of project types,
technologies and interventions is clearly unrealistic.
However, it is noted that managers of public health






























Total TB Incidence (New Cases)
Total TB Incidence and Treatment Cost
Figure 5 TB incidence and treatment cost per patient (2010).
Source: WHO [1].evaluation of a proposed new program [personal
communication from Dr Anban Pillay of the National
Department of Health, South Africa]. Below this
value, the cost of implementation is considered to
exceed the extent of the savings, such costs being
typically associated with activities such as the revision
of guidelines, training of personnel and amendments
to tendering procedures. As a conservative estimate, it
is therefore assumed that the R&D outcomes will at a
minimum achieve the 15% hurdle rate.
In many cases, the annual savings will be higher. For
instance, a new TB drug which will reduce treatment time
from 6 months to 2 months, number of drugs from 4 to 2,
and the daily drug dose from 1,625 mg (pyrazinamide) to
200 mg (delamanid) could decrease the TB treatment cost
per patient from in excess of $30 to $20.
 rNPV of future savings: the risk adjusted NPV of the
future savings depends on the expected duration of
the savings, the perceived risk and the discount rate.
The latter has been assumed previously at 8% and
the average expected duration as 15 years. The



































Present and Recommended Response to Disease Burden by Country
(Bubble Size is TB Incidence)
Figure 7 Actual and recommended TB R&D expenditure. Source:
WHO [1] and G-FINDER [24].
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higher risk than a new diagnostics project.
Nevertheless, across a whole portfolio of health
R&D projects, the average risk factor, based on the
weighted average success rates (Additional file 1:
Table S4) will be about 30%.
It is now possible to estimate the RoI factor for national
TB R&D programs, and by extrapolation to other indica-
tions, for all national health R&D. The results of the calcu-
lations for both Global Justice Index and RoI factor
are shown in Figure 6; these recommended values are
compared against actual values in Figure 7.
Based on this approach, the South African TB R&D
allocation should be $92 million per annum, of which
the bulk can be justified solely on the basis of the RoI
Factor. Interestingly, the present TB expenditure of both
the United States and the United Kingdom are already
close to the recommended levels (90% and 94% of the
calculated targets, respectively); however China, South
Africa and Japan are below 1% of the target, and consid-
erable increases in their respective TB R&D budgets are
both required and justifiable.Conclusions
Although the moral and legal obligation (within the global
justice framework) of high-income countries to the support
of health research has been persuasively and extensively
argued [26,27], no studies have been published on the
extent of this obligation [22]. Moreover it can be argued
that high-burden countries could realize a significant
return on investment from neglected disease R&D through
savings to public expenditure as a consequence of
improved treatment regimens, diagnostics, vaccines and
operations. The quantity of both this obligation and oppor-
tunity are the focus of this article. By considering the two
separate concepts of global justice and return on invest-
ment, a methodology for calculating the scale of any
country’s investment in TB R&D as a function of both per
capita income and disease incidence has been defined.
The recent CEWG report concludes that “a binding
instrument on R&D is necessary to secure appropriate
funding and coordination to promote R&D needed to
address the diseases that disproportionately affect devel-
oping countries and which constitute a common global
responsibility” [22], and proposes a target of 0.01% of
GDP for government-funded R&D be devoted to the
health needs of developing countries, with little
explanation of, or justification for, how the value was
obtained. This paper goes some way towards defining how
such a binding instrument could be constructed and
proportioned at the level of a specific disease, and the
extent of this responsibility for all countries.It is not possible to directly compare the new target to
the CEWG proposal, since the latter refers only to health
needs in general and this study deals specifically with
TB. However, the new target is mostly between 5% and
10% of the CEWG proposal, suggesting that relative to
other priorities TB R&D should be a focus of neglected
disease research in most countries, and especially
high-burden countries.Additional file
Additional file 1: Appendix A. Data on TB treatment cost and disease
burden in South Africa. Appendix B. Costs of TB Drug Development [36,37].
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